An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)

RecruitingOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Ulcerative Colitis
Trial Locations (5)

1407

RECRUITING

Acibadem City Clinic Tokuda University Hospital, Sofia

8800

RECRUITING

AZ Delta vzw, Roeselare

16777

RECRUITING

"General Hospital of Athens Evangelismos", Ellinikó

28202

RECRUITING

Imelda General Hospital, Bonheiden

44307

NOT_YET_RECRUITING

Lithuanian University of Life Sciences, Kaunas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

OTHER